

KFIN/GXP/DEC/2021
January 5, 2022

Mr. Ajay Nadkarni
M/s. GlaxoSmithKline Pharmaceuticals Limited
Dr. Annie Besant Road
Worli Mumbai-400025.

Sub: Investor Grievance Certificate for the quarter ended December 31, 2021

Dear Sir,


With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended December 31, 2021.

Description of Complaint	Opening Balance as on 01.10.2021	Received during the Period 01.10.2021 to 31.12.2021	Attended/Resolved during the Period 01.10.2021 to 31.12.2021	Pending as on 31.12.2021
Non-receipt of Dividend	NIL	23	23	NIL
Non-receipt of Annual reports	NIL	NIL	NIL	NIL
Non receipt of share certificates	NIL	02	02	NIL
SEBI	NIL	02	02	NIL
Stock Exchange	NIL	04	03	01
Total	NIL	31	30	01

This is for your information and record.

Thanking you,

Yours faithfully
For KFin Technologies Private Limited



Rajitha Cholleti
Asst. General Manager